Clarivate PLC
CLVT
ISIN JE00BJJN4441 / Valor 47927463
Clarivate PLC
UMushroom community rating:
About company
Clarivate PLC is a global company that specializes in providing critical insights, analytics, and workflow solutions across various domains of knowledge, research, and innovation. With a workforce of over 11,000 employees worldwide, including industry specialists, consultants, and data scientists, Clarivate caters to the needs of more than 45,000 customers globally. The company's offerings are particularly notable in the biopharmaceutical sector, where it has been a partner to leading companies for over 25 years, assessing R&D and clinical productivity and delivering actionable data and insights. One of its recent innovations is the VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence, which offers predictive compound safety and efficacy insights. As a publicly traded entity on the New York Stock Exchange under the ticker NYSE:CLVT, Clarivate leverages its deep domain expertise to provide subscription and technology-based solutions that support the research and innovation ecosystem. The company's commitment to transforming perspectives and work through trusted intelligence is evident in its comprehensive approach to connecting people and organizations with the information they need to succeed.
Summarized from source with an LLMView SourceSector: FinanceLatest Results (04.10.2025):
Clarivate PLC reported its financial results for the first quarter of 2025, demonstrating a slight decline in total revenues compared to the same period last year. Despite a decrease in overall revenue, the company achieved modest growth in organic recurring revenues and continued to execute its Value Creation Plan effectively. Additionally, Clarivate reaffirmed its outlook for the full year 2025, reflecting confidence in its long-term growth strategy.
Revenue Performance
Total revenues for Clarivate PLC in Q1 2025 were $593.7 million, a decrease of 4.4% compared to $621.2 million in Q1 2024. Organic revenues saw a marginal increase of 0.3%, driven by a 0.6% rise in organic recurring revenues, which was partially offset by a decline in organic transactional revenues.
Net Income and Earnings
Clarivate reported a net loss of $103.9 million, or $0.15 per diluted share, for Q1 2025, compared to a net loss of $75.0 million, or $0.14 per diluted share, in the same quarter last year. Adjusted net income decreased to $95.8 million, and Adjusted EBITDA slightly declined to $233.2 million.
Cash Flow and Share Repurchase
The company generated $171.2 million in operating cash flow and $110.3 million in free cash flow during the first quarter. Additionally, Clarivate repurchased $50.0 million of its ordinary shares, aligning with its capital allocation strategy to return value to shareholders.
2025 Outlook Reaffirmed
Clarivate reaffirmed its full-year 2025 outlook, projecting revenues between $2.28 billion and $2.40 billion and Adjusted EBITDA ranging from $940 million to $1.00 billion. The company remains confident in achieving its long-term growth objectives despite a volatile macroeconomic environment.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2265 M
Market cap (USD)
4,828,259
Daily traded volume (Shares)
5.105 / 4.95
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
